Literature DB >> 27730399

Elevated Serum Carcinoembryonic Antigen Is Associated with a Worse Survival Outcome of Patients After Liver Resection for Hepatocellular Carcinoma: a Propensity Score Matching Analysis.

Jianwei Liu1,2, Yong Xia1, Lehua Shi1, Xifeng Li1, Lu Wu1, Zhenlin Yan3.   

Abstract

BACKGROUND: The relationship between serum carcinoembryonic antigen (CEA) and postoperative prognosis in hepatocellular carcinoma (HCC) has not been reported.
METHODS: Data of 5410 consecutive HCC patients who underwent hepatectomy was retrospectively reviewed. Survival curves for overall survival (OS) and tumor recurrence (TR) were depicted using the Kaplan-Meier method and compared using the log-rank test. Independent risk factors of OS and TR were analyzed with Cox hazard regression model. Besides, a one-to-one propensity score-matched (PSM) subset was performed to reduce selection bias. Subgroup analysis was done according to hepatitis B virus (HBV) infection or not.
RESULTS: Serum CEA ≥5.1 μg/L was an independent risk factor of OS and TR in the entire cohort and PSM subset (OS-hazard ratio = 1.218, 95 % confidence interval = 1.060-1.400; 1.383, 1.133-1.688, respectively; TR-1.256, 1.114-1.417; 1.258, 1.067-1.484, respectively). Subgroup analysis showed that CEA ≥5.1 μg/L was an independent risk factor of OS and TR in the HBV infection group (OS-1.234, 1.065-1.429; TR-1.231, 1.083-1.399) but not in the non-HBV infection group (OS-1.376, 0.895-2.117; TR-1.437, 0.989-2.088).
CONCLUSION: Serum CEA ≥5.1 μg/L was an independent risk factor of OS and TR of HCC patients, and patients with CEA ≥5.1 μg/L had poorer prognosis, especially for HCC patients with HBV infection.

Entities:  

Keywords:  Carcinoembryonic antigen; Hepatocellular carcinoma; Prognosis; Tumor marker

Mesh:

Substances:

Year:  2016        PMID: 27730399     DOI: 10.1007/s11605-016-3295-8

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  38 in total

Review 1.  Early detection and treatment of cholangiocarcinoma.

Authors:  G J Gores
Journal:  Liver Transpl       Date:  2000-11       Impact factor: 5.799

2.  Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

Authors:  R B D'Agostino
Journal:  Stat Med       Date:  1998-10-15       Impact factor: 2.373

Review 3.  Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy.

Authors:  Ching-Lung Lai; Man-Fung Yuen
Journal:  Hepatology       Date:  2013-01       Impact factor: 17.425

Review 4.  The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues.

Authors:  S Hammarström
Journal:  Semin Cancer Biol       Date:  1999-04       Impact factor: 15.707

5.  Diagnostic accuracy of serum-carcinoembryonic antigen in recurrent colorectal cancer: a receiver operating characteristic curve analysis.

Authors:  Hartwig Körner; Kjetil Söreide; Pål Johan Stokkeland; Jon Arne Söreide
Journal:  Ann Surg Oncol       Date:  2007-02       Impact factor: 5.344

Review 6.  Lewis blood group and CEA related antigens; coexpressed cell-cell adhesion molecules with roles in the biological progression and dissemination of tumours.

Authors:  D S Sanders; M A Kerr
Journal:  Mol Pathol       Date:  1999-08

Review 7.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

8.  Lead time of carcinoembryonic antigen elevation in the postoperative follow-up of colorectal cancer did not affect the survival rate after recurrence.

Authors:  Chin-Hsin Chen; Mon-Chau Hsieh; Cheng-Chou Lai; Chien-Yuh Yeh; Jinn-Shiun Chen; Pao-Shiu Hsieh; Jy-Ming Chiang; Wen-Sy Tsai; Reiping Tang; Chung-Rong Changchien; Jeng-Yi Wang
Journal:  Int J Colorectal Dis       Date:  2010-02-17       Impact factor: 2.571

9.  Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes.

Authors:  Shimul A Shah; Sean P Cleary; Alice C Wei; Ilun Yang; Bryce R Taylor; Alan W Hemming; Bernard Langer; David R Grant; Paul D Greig; Steven Gallinger
Journal:  Surgery       Date:  2006-11-01       Impact factor: 3.982

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  1 in total

1.  A retrospective discussion of the prognostic value of combining prothrombin time(PT) and fibrinogen(Fbg) in patients with Hepatocellular carcinoma.

Authors:  Xue-Ping Wang; Min-Jie Mao; Zhong-Lian He; Lin Zhang; Pei-Dong Chi; Jia-Rui Su; Shu-Qin Dai; Wan-Li Liu
Journal:  J Cancer       Date:  2017-07-05       Impact factor: 4.207

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.